We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By continuing to use the website, you consent to our use of cookies.
Scrip is part of Pharma Intelligence UK Limited
This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.
This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183
Latest public offering nets $601mm for bluebird bio
31 Jul 2018
Executive Summary
Immunotherapy and gene editing firm bluebird bio Inc. netted $601mm through the public offering of 3.9mm common shares (including the overallotment) at $162.50. Proceeds are earmarked for the following: future development of a gene therapy for severe sickle cell disease; the company's portion of development, manufacturing, and commercialization costs related to multiple myeloma CART therapy bb2121, in partnership with Celgene; Phase I study of bb21217, also for multiple myeloma and part of the Celgene agreement; Phase III trial of LentiGlobin candidate HGB212 for transfusion-dependent beta-thalassemia; continued advancement of the company's commercial infrastructure to support upcoming product launches in the US and Europe; and for ongoing manufacturing and R&D needs.
Deal Industry
Pharmaceuticals
Pharmaceuticals
Drug Delivery
Macromolecule
Biotechnology
Gene Therapy, Cell Therapy
Large Molecule
Deal Status
Final
Deal Type
Financing
FOPO
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?